Identification of prognostic molecular biomarkers in 157 HPV-positive and HPV-negative squamous cell carcinomas of the oropharynx.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
01 12 2019
Historique:
received: 09 02 2019
revised: 23 04 2019
accepted: 30 04 2019
pubmed: 17 5 2019
medline: 1 2 2020
entrez: 17 5 2019
Statut: ppublish

Résumé

The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been increasing due to high-risk HPV infection. We explored the significance of genetic alterations in HPV-positive (HPV-P) and HPV-negative (HPV-N) OPSCC patients on long-term outcome. A total of 157 cases of primary resected OPSCC diagnosed from 1978 to 2005 were subjected to a targeted exome sequencing by MSK-IMPACT™ interrogating somatic mutations in 410 cancer-related genes. Mutational profiles were correlated to recurrence and survival outcomes. OPSCC included 47% HPV-positive (HPV-P) and 53% HPV-negative (HPV-N) tumors arising in the base of tongue (BOT, 43%), palatine tonsil (30%) and soft palate (SP, 27%). HPV negative status, SP location and smoking were associated with poorer outcome. Poorer overall survival was found in NOTCH1-mutated HPV-P (p = 0.039), and in SOX2-amplified HPV-N cases (p = 0.036). Chromosomal arm gains in 8p and 8q, and 16q loss were more common in HPV-P (p = 0.005, 0.04 and 0.01, respectively), while 9p, 18q and 21q losses were more frequent in HPV-N OPSCC (p = 0.006, 0.002 and 0.01, respectively). Novel, potentially functional JAK3, MYC and EP300 intragenic deletions were found in HPV-P, and FOXP1, CDKN2A, CCND1 and RUNX1 intragenic deletions and one FGFR3 inversion were detected in HPV-N tumors. HPV-N/TP53-wild-type OPSCC harbored recurrent mutations in NOTCH1/3/4 (39%), PIK3CA, FAT1 and TERT. In comparison to their oral and laryngeal counterparts, HPV-N OPSCC were genetically distinct. In OPSCC, HPV status, tumor subsite and smoking determine outcome. Risk-stratification can be further refined based on the mutational signature, namely, NOTCH1 and SOX2 mutation status.

Identifiants

pubmed: 31093971
doi: 10.1002/ijc.32412
pmc: PMC7595146
mid: NIHMS1635629
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3152-3162

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA172012
Pays : United States

Informations de copyright

© 2019 UICC.

Références

Science. 2011 Aug 26;333(6046):1157-60
pubmed: 21798893
Clin Cancer Res. 2018 Dec 15;24(24):6308-6318
pubmed: 30087145
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Nat Rev Cancer. 2011 Jan;11(1):9-22
pubmed: 21160525
J Natl Cancer Inst. 2000 May 3;92(9):709-20
pubmed: 10793107
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Am J Surg Pathol. 2011 Sep;35(9):1343-50
pubmed: 21836494
Stem Cell Reports. 2015 Dec 8;5(6):1210-1225
pubmed: 26527383
N Engl J Med. 2007 Dec 20;357(25):2552-61
pubmed: 18094376
J Natl Cancer Inst. 2008 Feb 20;100(4):261-9
pubmed: 18270337
Ann Surg Oncol. 2015 Dec;22(13):4411-21
pubmed: 25801358
J Clin Oncol. 2015 Mar 10;33(8):836-45
pubmed: 25667292
Clin Cancer Res. 2015 Feb 1;21(3):632-41
pubmed: 25056374
Carcinogenesis. 2014 Jul;35(7):1636-42
pubmed: 24743512
Ann Oncol. 2016 Dec;27(12):2262-2268
pubmed: 27681865
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75
pubmed: 15734974
J Mol Diagn. 2015 Sep;17(5):576-82
pubmed: 26165824
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Clin Cancer Res. 2014 Feb 1;20(3):701-10
pubmed: 24277457
Laryngoscope Investig Otolaryngol. 2017 Jan 17;2(1):10-18
pubmed: 28894817
Int J Cancer. 2011 Apr 1;128(7):1596-605
pubmed: 20499310
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Cancer. 2013 Jan 1;119(1):81-9
pubmed: 22736261
Science. 2011 Aug 26;333(6046):1154-7
pubmed: 21798897
Mol Oncol. 2015 Oct;9(8):1704-19
pubmed: 26040981
JAMA Oncol. 2017 Feb 1;3(2):244-255
pubmed: 27442865
Br J Cancer. 2016 Jan 19;114(2):199-206
pubmed: 26742007
Int J Clin Exp Med. 2014 Dec 15;7(12):5010-20
pubmed: 25664000
New Microbiol. 2014 Apr;37(2):129-43
pubmed: 24858640
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821

Auteurs

Snjezana Dogan (S)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.

Bin Xu (B)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.

Sumit Middha (S)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.

Chad M Vanderbilt (CM)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.

Anita S Bowman (AS)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.

Jocelyn Migliacci (J)

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Luc G T Morris (LGT)

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Venkatraman E Seshan (VE)

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.

Ian Ganly (I)

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH